Imperial College London
Portrait Picture

Dr Rodrigo M. Carrillo Larco

Faculty of Medicine, School of Public Health

 
 
 
//

Contact

 

r.carrillo-larco CV

 
 
//

Location

 

Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Carrillo-Larco:2020:10.12688/wellcomeopenres.15987.1,
author = {Carrillo-Larco, R and Altez-Fernandez, C and Ravaglia, S and Vizcarra, J},
doi = {10.12688/wellcomeopenres.15987.1},
journal = {Wellcome Open Research},
pages = {1--12},
title = {COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports},
url = {http://dx.doi.org/10.12688/wellcomeopenres.15987.1},
volume = {5},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Guillain-Barre Syndrome (GBS) is a neurological autoimmune disease that can lead to respiratory failure and death. Whether COVID-19 patients are at high risk of GBS is unknown. Through a systematic review of case reports, we aimed to summarize the main features of patients with GBS and COVID-19. Methods: Without any restrictions, we searched MEDLINE, Embase, Global Health, Scopus, Web of Science and MedXriv (April 23 rd , 2020). Two reviewers screened and studied titles, abstracts and reports. We extracted information to characterize sociodemographic variables, clinical presentation, laboratory results, treatments and outcomes. Results: Eight reports (n=12 patients) of GBS and COVID-19 were identified; one was a Miller Fisher case. Overall, the median age was 62.5 (interquartile range (IQR)=54.5-70.5) years, and there were more men (9/102). GBS symptoms started between 5 and 24 days after those of COVID-19. The median protein levels in cerebrospinal fluid samples was 101.5 mg/dl (IQR=51-145). None of the cerebrospinal fluid samples tested positive for COVID-19. Six patients debuted with ascendant weakness and three with facial weakness. Five patients had favourable evolution, four remained with relevant symptoms or required critical care and one died; the Miller Fisher case had successful resolution. Conclusions: GBS is emerging as a disease that may appear in COVID-19 patients. Although limited, preliminary evidence appears to suggest that GBS occurs after COVID-19 onset. Practitioners and investigators should have GBS in mind as they look after COVID-19 patients and conduct research on novel aspects of COVID-19. Comparison with GBS patients in the context of another viral outbreak (Zika), revealed similarities and differences that deserves further scrutiny and epidemiological studies.
AU  - Carrillo-Larco,R
AU  - Altez-Fernandez,C
AU  - Ravaglia,S
AU  - Vizcarra,J
DO  - 10.12688/wellcomeopenres.15987.1
EP  - 12
PY  - 2020///
SN  - 2398-502X
SP  - 1
TI  - COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports
T2  - Wellcome Open Research
UR  - http://dx.doi.org/10.12688/wellcomeopenres.15987.1
UR  - https://wellcomeopenresearch.org/articles/5-107/v1
UR  - http://hdl.handle.net/10044/1/96304
VL  - 5
ER  -
Download